Minerva's shares are crumbling today on the heels of a major clinical setback.
News & Analysis: Minerva Neurosciences
NERV earnings call for the period ending September 30, 2019.
Two healthcare stocks, two plunging stock prices, and two unique scenarios heading into the end of 2019.
A cyberattack resulted in a clinical trial delay. Really.
NERV earnings call for the period ending June 30, 2019.
NERV earnings call for the period ending March 31, 2019.
NERV earnings call for the period ending December 31, 2018.
These two news items were the primary reasons that Minerva's stock shed nearly a third of its value last month.
Minerva Neurosciences and Johnson & Johnson have amended their co-development agreement for the experimental insomnia drug MIN-202.